TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05975554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 [IL-2]
Description: 5 sequential days of treatment (1.5MIU/day subcutaneously)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care - Carotid Endarterectomy
Description: Standard care for patients with carotid stenosis undergoing carotid endarterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard care - Carotid Endarterectomy
Description: Standard care for patients with carotid stenosis undergoing carotid endarterectomy
Study: NCT04921761

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional epidural
Description: In this group, a 20-gauge multi-orifice catheter was threaded through the cephalic-directed tip of the epidural needle 5 cm into the epidural space.
Study: NCT04832971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-ANG3
Description: ARO-ANG3 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-ANG3
Description: ARO-ANG3 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARO-ANG3
Description: ARO-ANG3 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Normal Saline (0.9% NaCl)
Study: NCT06077929

Intervention type: OTHER
Intervention: No intervention done
Description: No interventions done
Study: NCT05290233

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRE + Exercise
Description: We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRE + Exercise
Description: We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise
Study: NCT05321875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan
Description: 3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
Study: NCT06078540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USeeBP
Description: USeeBP is a low risk mobile medical app that proposes to do no more than:~* Help patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions;~* Provide patients with simple tools to organize and track their health information;~* Provide easy access to information related to patients' health conditions or treatments;~* Help patients document, show, or communicate potential medical conditions to health care providers;
Study: NCT04921761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural puncture epidural
Description: In this group, the dura was punctured by 25G Whitacre needle. After confirmation of CSF flow, the needle was removed and the epidural catheter was threaded.
Study: NCT04570761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dreem headband
Description: acoustic stimulation
Study: NCT06109857

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT04570761

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dreem headband
Description: acoustic stimulation
Study: NCT06478043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivonescimab
Description: 20mg/kg, IV, D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome
Description: 56.5mg/m\^2, IV, D1, Q2W
Study: NCT05509439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Transfusion Program Components
Description: The Home Transfusion Program will include trained transfusion nurse(s) who will administer transfusions in the home setting. The transfusion nurse, who is part of the study team, will work closely with the DFCI/BWH Blood Bank and the hospice agency (Care Dimensions Inc.) that all study patients are enrolled in. The transfusion nurse will administer home transfusions using safe home transfusion practices endorsed by the AABB. The home transfusion program has 4 key aspects Initial home visit, (2) subsequent contact, (3) home transfusion assessment \& administration, (4) usual elements of hospice
Study: NCT06272201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POSE2.0 procedure with g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors
Description: POSE2.0 (g-Cath EZ snowshoe suture anchors placed in the mid + distal body without placement in the fundus), with a moderate intensity diet and exercise program
Study: NCT05212519

Intervention type: OTHER
Description: For observational research
Study: NCT06509139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Bismuth Subcitrate 120 MG Oral Tablet
Description: Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Bismuth Subcitrate 120 MG Oral Tablet
Description: Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Bismuth Subcitrate 120 MG Oral Tablet
Description: Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study: NCT06288919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol prophylactic powders
Description: erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic scaler with peek inserts
Description: ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
Study: NCT06043271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EMPOWER Program
Description: The EMPOWER Program is a web-based, self-administered SSI for parents that takes about 30 minutes to complete.
Study: NCT05203172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib only treatment
Description: Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Parent Studies C4211001 and C4211003 with water irrespective of food, continuously, starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib only Treatment
Description: Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib & Binimetinib Treatment
Description: Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Encorafenib & Binimetinib & Ribociclib
Description: Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binimetinib tablets BID. The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Encorafenib & Binimetinib & Cetuximab
Description: Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
Study: NCT05158192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin/Hesperidin (90/10) 500 mg Test Drug
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin/Hesperidin (90/10) 500 mg Reference Product
Description: Daflon (Trademark)
Study: NCT06509139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG
Description: Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG
Description: Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG
Description: Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline Pill
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline Pill
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline Pill
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study: NCT05276024

Intervention type: DEVICE
Intervention: iFuse Bedrock technique
Description: Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
Study: NCT04815278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Chronic Disease Prevention Program (CDPP)
Description: The CDPP is an adaptation of the Diabetes Prevention Program (DPP). It will take place over a 24 week period and involve online instruction and individualized lifestyle coaching sessions. The online classroom curriculum includes 8 modules: Goal setting, self-monitoring and problem solving (M1), Managing stress and negative thoughts (M2), Healthy eating (M3), Taking more steps (M4), Keeping alcohol in check (M5), Lifestyle change (M6), Taking charge of what (and who) is around you (M7), and Staying motivated (M8). The lifestyle coaches will meet in person and over the phone intermittently over the 24 week period (Weeks 2, 4, 6, 10, 12, 16, 24).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Chronic Disease Prevention Program (CDPP)
Description: The CDPP is an adaptation of the Diabetes Prevention Program (DPP). It will take place over a 24 week period and involve online instruction and individualized lifestyle coaching sessions. The online classroom curriculum includes 8 modules: Goal setting, self-monitoring and problem solving (M1), Managing stress and negative thoughts (M2), Healthy eating (M3), Taking more steps (M4), Keeping alcohol in check (M5), Lifestyle change (M6), Taking charge of what (and who) is around you (M7), and Staying motivated (M8). The lifestyle coaches will meet in person and over the phone intermittently over the 24 week period (Weeks 2, 4, 6, 10, 12, 16, 24).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace Equity, Job and Health Supports Employer Intervention
Description: The employer intervention combines implicit bias awareness training for supervisors of hired DSS-E clients, and regular, structured, interactions between supervisors and DSS-E hires.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace Equity, Job and Health Supports Employer Intervention
Description: The employer intervention combines implicit bias awareness training for supervisors of hired DSS-E clients, and regular, structured, interactions between supervisors and DSS-E hires.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed, attenuated Chronic Disease Prevention Program (CDPP)
Description: Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
Study: NCT04263831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (aldesleukin).
Description: Description of intervention is covered in Arm, above.
Study: NCT05927584

Intervention type: PROCEDURE
Intervention: Transanal local excision
Description: Transanal full thickness local excision
Study: NCT04543838

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP) intraoperative monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care BP management
Description: If blood pressure (BP) control is determined to be necessary, standard of care practices to manage it will be implemented
Study: NCT04067752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high dialysate sodium concentration (138 mEq/L)
Description: high dialysate sodium concentration (138 mEq/L)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low dialysate sodium concentration
Description: low dialysate sodium concentration (132 mEq/L)
Study: NCT05663502

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and/or tumor tissue sample collection
Study: NCT05602870

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)
Description: A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
Study: NCT05438888

Intervention type: DRUG
Intervention: Warfarin
Description: This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.

Intervention type: DRUG
Intervention: Apixaban
Description: This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
Study: NCT04845477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic tape
Description: magnetic tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology tape
Description: kinesiology tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
Study: NCT06061341

Intervention type: DIAGNOSTIC_TEST
Intervention: TruGraf®
Description: TruGraf® is a non-invasive blood-based test to assist the clinician in lowering immunosuppression in liver transplant patients. It is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients.
Study: NCT06677021

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Physical activity promotion and engagement
Study: NCT06680102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
Study: NCT06681610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation
Description: low intensity shock-waves stimulation of the motor cortex, bilateral

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Pulse Stimulation
Description: low intensity shock-waves stimulation of the motor cortex, bilateral
Study: NCT06680544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole high dose
Description: Oral voriconazole 200mg once a day for a maximum of 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole low dose
Description: Oral voriconazole 200mg twice a day for a maximum of 28 days
Study: NCT05396846

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eating Plan 1
Description: The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Plan 2
Description: The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Plan 3
Description: The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
Study: NCT06621719

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar Cleft Reconstruction
Description: Alveolar Cleft Reconstruction Using Bone Matrix Prepared from Cancellous Particulates Mixed with Albumin-PRF in study group versus L-PRF in control group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar Cleft Reconstruction
Description: Alveolar Cleft Reconstruction Using Bone Matrix Prepared from Cancellous Particulates Mixed with Albumin-PRF in study group versus L-PRF in control group
Study: NCT06681805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine + Bupivacaine + Morphine
Description: Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5% along with 0.2 mg of morphine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine + Bupivacaine + Morphine
Description: Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Bupivacaine + Morphine
Description: Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.2 mg of morphine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ Bupivacaine + Morphine
Description: Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
Study: NCT06681298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The experimental group received Nivolumab
Description: Trastuzumab and the FLOT chemotherapy regimen are clearly recommended by guidelines, whereas Nivolumab is currently requiring further research validation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The experimental group received Nivolumab
Description: Trastuzumab and the FLOT chemotherapy regimen are clearly recommended by guidelines, whereas Nivolumab is currently requiring further research validation.
Study: NCT06681142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy-Physiotherapy Intervention
Description: Pharmacists will provide comprehensive 1:1 patient care, including a complete patient assessment and medication review, provide specific drug therapy recommendation(s) using shared decision making (SDM), and provide patient education, including further written materials.~Participants will be offered either individual or group physiotherapy sessions at the a private clinic.
Study: NCT05215886

Intervention type: BEHAVIORAL
Intervention: Surgery
Description: Study subjects scheduled for or have already completed weight loss surgery and have already completed psychological screening as part of their pre-surgery work up
Study: NCT06289985

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular thrombectomy with any FDA-approved category POL or NRY device
Description: Endovascular thrombectomy with any FDA-approved category POL or NRY device - Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL), and/or Catheter, Thrombus Retriever (NRY)

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular thrombectomy with any FDA-approved category POL or NRY device
Description: Endovascular thrombectomy with any FDA-approved category POL or NRY device - Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL), and/or Catheter, Thrombus Retriever (NRY)

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Management
Description: Medical Management (MM) may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care.

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Management
Description: Medical Management (MM) may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care.